J van de Wetering
Overview
Explore the profile of J van de Wetering including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hezer B, Reinders M, van den Hoogen M, Tielen M, van de Wetering J, Hesselink D, et al.
Transpl Int
. 2024 Aug;
37:13192.
PMID: 39104837
After transplantation self-management is essential for graft survival and optimal quality of life. To address the need for home-based support in self-management, we implemented the "SelfCare after Renal Transplantation" (SeCReT)...
2.
Tramper T, Roelen D, Brand-Schaaf S, Kal-van Gestel J, Kho M, Reinders M, et al.
Front Immunol
. 2023 Jan;
13:1093359.
PMID: 36703958
Background: The impact of donor-specific antibodies (DSA) in (highly-) immunized living donor kidney transplant recipients is reported differentially in various patient cohorts. Methods: We have performed a retrospective analysis of...
3.
Oudmaijer C, Minnee R, Pol R, van den Boogaard W, Komninos D, van de Wetering J, et al.
Trials
. 2022 Jan;
23(1):18.
PMID: 34991694
Background: One of the main effectors on the quality of life of living-kidney donors is postoperative fatigue. Caloric restriction (CR) and short-term fasting (STF) are associated with improved fitness and...
4.
Predictors of postoperative cardiovascular complications up to 3 months after kidney transplantation
den Dekker W, Slot M, Kho M, Galema T, van de Wetering J, Boersma E, et al.
Neth Heart J
. 2020 Feb;
28(4):202-209.
PMID: 32067214
Background: Renal transplant patients have a high peri-operative risk for cardiovascular events. Pre-operative screening for cardiac ischaemia might lower this risk, but there are no specific guidelines. Methods: We conducted...
5.
Peters F, Peeters A, van den Bosch T, Mooyaart A, van de Wetering J, Betjes M, et al.
Clin Exp Immunol
. 2019 May;
197(3):341-351.
PMID: 31059128
Cutaneous squamous cell carcinoma (cSCC) is a serious complication after organ transplantation and patients benefit from an early risk assessment. We hypothesized that functional differences in circulating T cells may...
6.
Bouamar R, Shuker N, Osinga J, Clahsen-van Groningen M, Damman J, Baan C, et al.
Neth J Med
. 2018 Jan;
76(1):14-26.
PMID: 29380728
Background: While conversion from cyclosporine to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomised, controlled trial the safety and tolerability of switching from tacrolimus...
7.
Minnee R, Kimenai H, van de Wetering J, IJzermans J
Case Rep Transplant
. 2017 Jun;
2017:8286257.
PMID: 28660086
Ectopic pelvic kidneys can provide an additional source of organs for transplantation. They are often excluded from donation in living donation programs mainly due to aberrant vascular and urinary anatomies....
8.
Shuker N, Bouamar R, van Schaik R, Clahsen-van Groningen M, Damman J, Baan C, et al.
Am J Transplant
. 2015 Dec;
16(7):2085-96.
PMID: 26714287
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This randomized-controlled study investigated whether adaptation of the tacrolimus starting...
9.
Schmitt-Hoffmann A, Roos B, Schoetzau A, Leese P, Meyer I, van de Wetering J, et al.
Expert Rev Clin Pharmacol
. 2012 Sep;
5(4):373-88.
PMID: 22943117
Alitretinoin is an endogenous retinoid related to vitamin A. Studies have shown that oral alitretinoin is effective and well tolerated in the treatment of severe chronic hand eczema. This review...
10.
Bergmann J, de Bruijne J, Hotho D, de Knegt R, Boonstra A, Weegink C, et al.
Aliment Pharmacol Ther
. 2011 Jun;
34(4):443-53.
PMID: 21707679
Background: The ANA773 is an oral prodrug of a small-molecule toll-like receptor (TLR)7 agonist. Preclinical and healthy volunteer clinical studies with ANA773 have demonstrated induction of endogenous interferon-α (IFN-α) of...